Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Idiopathic myelofibrosis.

Giovanni Barosi1, Ronald Hoffman

  • 1Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo, Pavia, Italy.

Seminars in Hematology
|October 8, 2005
PubMed
Summary

Idiopathic myelofibrosis (IMF) involves bone marrow fibrosis and anemia. Key treatments include medications for anemia and chemotherapy for systemic symptoms, with stem cell transplantation offering a potential cure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.

British journal of haematology·2026
Same author

Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms.

Cancer cell·2026
Same author

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> Mutation.

bioRxiv : the preprint server for biology·2026
Same author

Understanding the link between PMN-MDSCs and CXCL8-CXCR1/2 axis in primary myelofibrosis.

Frontiers in cell and developmental biology·2026
Same author

Response to Comment on: "Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm."

Haematologica·2026
Same author

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Leukemia & lymphoma·2026

Area of Science:

  • Hematology
  • Oncology

Background:

  • Idiopathic myelofibrosis (IMF) presents with anemia, splenomegaly, and bone marrow fibrosis.
  • Transitional myeloproliferative disorder (MPD) and myelofibrosis with fatty bone marrow share IMF features but have distinct clinical characteristics.
  • Constitutive mobilization of hematopoietic progenitor cells (HPCs) and endothelial progenitor cells (EPCs) is a unique biomarker for IMF.

Purpose of the Study:

  • To outline the diagnostic and prognostic parameters for Idiopathic myelofibrosis.
  • To review current therapeutic strategies for managing IMF.
  • To discuss the role of allogeneic stem cell transplantation in IMF treatment.

Main Methods:

  • Prognostic scoring using hemoglobin, white blood cell count, and peripheral blast count.
  • Pharmacological treatments including androgens, rHuEpo, and thalidomide for anemia.
  • Chemotherapy (e.g., hydroxyurea) for systemic symptoms of myeloproliferation.
  • Allogeneic stem cell transplantation with myeloablative and reduced-intensity conditioning (RIC) regimens.

Main Results:

  • Prognostic scores aid in therapeutic decision-making.
  • Anemia of IMF can be effectively treated with androgens, rHuEpo, and thalidomide.
  • Hydroxyurea is a common treatment for systemic symptoms.
  • Allogeneic stem cell transplantation offers curative potential.
  • RIC regimens improve survival and reduce transplant-related mortality compared to myeloablative regimens.

Conclusions:

  • Idiopathic myelofibrosis requires tailored treatment based on prognostic factors.
  • A multi-modal approach involving medical therapy and potentially transplantation is crucial for managing IMF.
  • Reduced-intensity conditioning regimens enhance the safety and efficacy of stem cell transplantation for IMF.

Related Experiment Videos